Cardiff Oncology, Inc. (NASDAQ:CRDF) Receives Average Rating of “Moderate Buy” from Analysts

Cardiff Oncology, Inc. (NASDAQ:CRDF) has received a consensus rating of “Moderate Buy” from the seven analysts that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $10.10.

CRDF has been the topic of several research reports. Wall Street Zen raised shares of Cardiff Oncology from a “sell” rating to a “hold” rating in a report on Wednesday, March 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cardiff Oncology in a research report on Wednesday, January 21st. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Cardiff Oncology in a report on Wednesday, January 28th. Noble Financial initiated coverage on Cardiff Oncology in a research report on Monday, January 5th. They issued an “outperform” rating and a $12.00 price target for the company. Finally, Piper Sandler decreased their price objective on Cardiff Oncology from $10.00 to $6.00 and set an “overweight” rating for the company in a research note on Wednesday, February 25th.

Institutional Investors Weigh In On Cardiff Oncology

Several institutional investors and hedge funds have recently made changes to their positions in CRDF. Capital Advisors Wealth Management LLC acquired a new stake in Cardiff Oncology during the 4th quarter worth about $30,000. Tamar Securities LLC acquired a new position in shares of Cardiff Oncology in the fourth quarter valued at about $32,000. Jeppson Wealth Management LLC purchased a new position in shares of Cardiff Oncology in the third quarter worth about $25,000. Brooklyn Investment Group purchased a new position in shares of Cardiff Oncology in the third quarter worth about $26,000. Finally, R Squared Ltd acquired a new stake in shares of Cardiff Oncology during the fourth quarter worth about $36,000. 16.29% of the stock is currently owned by institutional investors and hedge funds.

Cardiff Oncology Stock Up 0.5%

Shares of NASDAQ CRDF opened at $1.88 on Monday. Cardiff Oncology has a twelve month low of $1.48 and a twelve month high of $4.56. The firm has a market cap of $128.53 million, a PE ratio of -2.72 and a beta of 1.32. The business has a fifty day simple moving average of $2.21 and a two-hundred day simple moving average of $2.23.

Cardiff Oncology (NASDAQ:CRDF) last announced its quarterly earnings results on Tuesday, February 24th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.07. The firm had revenue of $0.24 million for the quarter, compared to analyst estimates of $0.13 million. Cardiff Oncology had a negative return on equity of 82.01% and a negative net margin of 7,733.22%. On average, research analysts expect that Cardiff Oncology will post -0.99 earnings per share for the current year.

About Cardiff Oncology

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.